EXEL - Exelixis, Inc.
| Previous Close | 27.17 |
| Open | 27.47 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 26.90 - 27.66 |
| 52 Week Range | 10.04 - 32.50 |
| Volume | 2,054,013 |
| Avg. Volume | 3,822,218 |
| Market Cap | 7.93B |
| Beta | 2.56 |
| PE Ratio (TTM) | 136.26 |
| EPS (TTM) | 0.2 |
| Earnings Date | Nov 1, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.29 |
- Motley Fool•3 days ago
Better Buy: Exelixis, Inc. vs. Intra-Cellular Therapies Inc.
Exelixis has enjoyed a meteoric rise already. Is it now time for Intra-Cellular Therapies to have its turn?
- Zacks•3 days ago
Cancer Treatment Update: Second Gene Therapy Receives Approval
The FDA approved Gilead's Yescarta for DLBCL, second CAR-T therapy in the United States. The regulatory authority also granted priority review to label expansion applications for four major cancer drugs.
- Capital Cube•4 days ago
ETFs with exposure to Exelixis, Inc. : October 20, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Exelixis, Inc. Here are 5 ETFs with the largest exposure to EXEL-US. Comparing the performance and risk of Exelixis, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- ACCESSWIRE•5 days ago
Exelixis, Positive News from Celestial Study, Cabometyx Label Review Due February 15, 2018
NEW YORK, NY / ACCESSWIRE / October 19, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...
- Business Wire•5 days ago
Exelixis to Release Third Quarter 2017 Financial Results on Wednesday, November 1, 2017
Exelixis, Inc. announced today that its third quarter 2017 financial results will be released on Wednesday, November 1, 2017 after the markets close. At 5:00 p.m. EDT / 2:00 p.m.
- ACCESSWIRE•6 days ago
Featured Company News - Exelixis' Cabozantinib Met Primary Endpoint in Phase-3 CELESTIAL Trial for Advanced Hepatocellular Carcinoma
LONDON, UK / ACCESSWIRE / October 18, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Exelixis, Inc. (NASDAQ: EXEL ), following which we have published a ...
- Zacks•6 days ago
Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug
Key highlights include regulatory updates from Exelixis (EXEL) and Spark Therapeutics and pipeline updates from Regeneron and Ionis among others.
- Zacks•7 days ago
FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx
Exelixis (EXEL) announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for kidney cancer drug Cabomteyx.
- Zacks•7 days ago
Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session
Exelixis (EXEL) was a big mover last session, as the company saw its shares rise more than 17% on the day amid huge volumes.
- Motley Fool•7 days ago
Why Exelixis' Rebound Is Just Getting Started
Buy the bounce? Signs point to "yes."
- ACCESSWIRE•7 days ago
Today's Research Reports on Stocks to Watch: Dynavax and Exelixis
NEW YORK, NY / ACCESSWIRE / October 17, 2017 / Dynavax saw some gains on Monday, though there was no major catalyst to explain the small and modest pop. Earlier in the month shares had broken out over ...
- Capital Cube•7 days ago
Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : October 17, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Exelixis, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
- Motley Fool•7 days ago
What Happened in the Stock Market Today
On another record day for major benchmarks, Exelixis soared on news about its cancer drug, and PG&E sank on concerns about a potential role in the California fires.
- Investor's Business Daily•7 days ago
Exelixis Rockets To 17-Year High On Kidney, Liver Cancer News
Exelixis popped early Monday after the FDA granted its drug, Cabometyx, priority review to treat advanced kidney cancer.
- Associated Press•7 days ago
Exelixis and Ruby Tuesday rise while Nordstrom and Tesla dip
Stocks that moved substantially or traded heavily Monday: Aramark, up 20 cents to $42.53 The food, facilities and uniform company agreed to make two acquisitions for $2.35 billion. Tesla Inc., down $4.97 ...
- GuruFocus.com•7 days ago
Wall Street High on Monday
Stocks jump in response to announcement and better rating
- Motley Fool•8 days ago
Why Exelixis, Inc. Rose Higher Today
Positive phase 3 data for Cabometyx in liver cancer sends shares of the biotech higher.
- TheStreet.com•8 days ago
Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers
The South San Francisco, Calif.-based company said Oct. 16 its Phase 3 study of cabozantinib achieved its primary endpoint of overall survival in patients that have advanced hepatocellular carcinoma.
- 24/7 Wall St.•8 days ago
Exelixis Cancer Treatment Hits Key Milestone
Exelixis kicked off the week with a couple updates that are already having a big impact on the stock. These updates came in the form of a key FDA approval.
- MarketWatch•8 days ago
Exelixis shares surge 19% premarket after FDA grants priority review to kidney cancer drug
Shares of biotech Exelixis Inc. rallied 19% in premarket trade Monday, after the company said it has won U.S. Food and Drug Administration priority review status for its supplemental New Drug Application ...
- Reuters•8 days ago
Exelixis cancer drug meets key goal in late-stage trial
Exelixis Inc said on Monday its drug met the main goal in a late stage study for treating patients with a type of liver cancer. The drug, Cabometyx, showed statistically significant improvement in overall ...
- Business Wire•8 days ago
Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma
Regulatory News:
- Business Wire•8 days ago
Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma
Exelixis, Inc. today announced that the U.S. Food and Drug Administration has determined the company’s supplemental New Drug Application for CABOMETYX® for patients with previously untreated advanced renal cell carcinoma to be sufficiently complete to permit a substantive review.
- Business Wire•8 days ago
Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma
Exelixis, Inc. today announced that its global phase 3 CELESTIAL trial met its primary endpoint of overall survival , with cabozantinib providing a statistically significant and clinically meaningful improvement in median OS compared to placebo in patients with advanced hepatocellular carcinoma .
